Loading...
Market
Will diagnosis rates for ATTR amyloidosis with cardiomyopathy increase by end of 2025?
2
Alnylam Pharmaceuticals•European Medicines Agency•Vutrisiran•Alnylam•Yvonne Greenstreet•STAT Summit•Greenstreet
Resolution / Starting Odds
Yes • 50%
No • 50%
Published medical research or reports from health organizations
Story
Alnylam Submits Regulatory Application for Vutrisiran, Predicts Multibillion-Dollar Product with 60% Success Rate
Oct 17, 2024, 01:30 PM
Alnylam Pharmaceuticals has submitted a regulatory application to the European Medicines Agency for its drug Vutrisiran, aimed at treating ATTR amyloidosis with cardiomyopathy. The submission reflects the company's strategic focus on expanding its product offerings in the competitive biotech landscape. Alnylam's CEO, Yvonne Greenstreet, expressed confidence in the drug's potential, predicting it could become a multibillion-dollar product despite rising competition. At the recent STAT Summit, Greenstreet highlighted a 60% probability of success for their RNAi drug development programs, emphasizing the importance of providing quality therapeutic options to stimulate diagnosis rates for rare conditions. The company, co-founded by former CEO J. Maraganore, is positioned to be a leading player in the biotech sector.
View original story
Similar markets
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Below $200,000 • 25%
$200,000 - $250,000 • 25%
$250,001 - $300,000 • 25%
Above $300,000 • 25%
Yes • 50%
No • 50%
Widely adopted (>75% of clinics) • 25%
Moderately adopted (50-75% of clinics) • 25%
Sparsely adopted (25-50% of clinics) • 25%
Rarely adopted (<25% of clinics) • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
No improvement • 25%
Slight improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%